Maternal buprenorphine treatment and fetal neurobehavioral development. 2017

Lauren M Jansson, and Martha Velez, and Krystle McConnell, and Nancy Spencer, and Michelle Tuten, and Hendree E Jones, and Van L King, and Neeraj Gandotra, and Lorraine A Milio, and Kristin Voegtline, and Janet A DiPietro
Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: ljansson@jhmi.edu.

Gestational opioid use/misuse is escalating in the United States; however, little is understood about the fetal effects of medications used to treat maternal opioid use disorders. The purpose of this study was to determine the effect of maternal buprenorphine administration on longitudinal fetal neurobehavioral development. Forty-nine buprenorphine-maintained women who attended a substance use disorder treatment facility with generally uncomplicated pregnancies underwent fetal monitoring for 60 minutes at times of trough and peak maternal buprenorphine levels. Data were collected at 24, 28, 32, and 36 weeks gestation. Fetal neurobehavioral indicators (ie, heart rate, motor activity, and their integration [fetal movement-fetal heart rate coupling]) were collected via an actocardiograph, digitized and quantified. Longitudinal data analysis relied on hierarchic linear modeling. Fetal heart rate, heart rate variability, and heart rate accelerations were significantly reduced at peak vs trough maternal buprenorphine levels. Effects were significant either by or after 28 weeks gestation and tended to intensify with advancing gestation. Fetal motor activity and fetal movement-fetal heart rate coupling were depressed from peak to trough at 36 weeks gestation. Polysubstance exposure did not significantly affect fetal neurobehavioral parameters, with the exception that fetuses of heavier smokers moved significantly less than those of lighter smokers at 36 weeks gestation. By the end of gestation, higher maternal buprenorphine dose was related to depression of baseline fetal cardiac measures at trough. Maternal buprenorphine administration has acute suppressive effects on fetal heart rate and movement, and the magnitude of these effects increases as gestation progresses. Higher dose (≥13 mg) appears to exert greater depressive effects on measures of fetal heart rate and variability. These findings should be balanced against comparisons to gestational methadone effects, relatively good outcomes of buprenorphine-exposed infants, and recognition of the benefits of medication-assisted treatment for pregnant women with opioid use disorders in optimizing pregnancy outcomes.

UI MeSH Term Description Entries
D009292 Narcotic Antagonists Agents inhibiting the effect of narcotics on the central nervous system. Competitive Opioid Antagonist,Narcotic Antagonist,Opioid Antagonist,Opioid Antagonists,Opioid Receptor Antagonist,Opioid Reversal Agent,Competitive Opioid Antagonists,Opioid Receptor Antagonists,Opioid Reversal Agents,Agent, Opioid Reversal,Agents, Opioid Reversal,Antagonist, Competitive Opioid,Antagonist, Narcotic,Antagonist, Opioid,Antagonist, Opioid Receptor,Antagonists, Competitive Opioid,Antagonists, Narcotic,Antagonists, Opioid,Antagonists, Opioid Receptor,Opioid Antagonist, Competitive,Opioid Antagonists, Competitive,Receptor Antagonist, Opioid,Receptor Antagonists, Opioid,Reversal Agent, Opioid,Reversal Agents, Opioid
D009293 Opioid-Related Disorders Disorders related to or resulting from abuse or misuse of OPIOIDS. Opiate Addiction,Opiate Dependence,Opioid Misuse,Opioid Use Disorder,Prescription Opioid Abuse,Prescription Opioid Misuse,Addiction, Opioid,Dependence, Opioid,Opiate Abuse,Opioid Abuse,Opioid Addiction,Opioid Dependence,Abuse, Opiate,Abuse, Opioid,Abuse, Prescription Opioid,Addiction, Opiate,Dependence, Opiate,Disorder, Opioid Use,Misuse, Opioid,Misuse, Prescription Opioid,Opiate Abuses,Opioid Abuse, Prescription,Opioid Abuses,Opioid Addictions,Opioid Dependences,Opioid Misuses,Opioid Related Disorders,Opioid Use Disorders,Opioid-Related Disorder,Prescription Opioid Abuses,Prescription Opioid Misuses
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D002047 Buprenorphine A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use. 6029-M,Buprenex,Buprenorphine Hydrochloride,Buprex,Prefin,RX-6029-M,Subutex,Temgesic,Temgésic,6029 M,6029M,Hydrochloride, Buprenorphine,RX 6029 M,RX6029M
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D005324 Fetal Movement Physical activity of the FETUS in utero. Gross or fine fetal body movement can be monitored by the mother, PALPATION, or ULTRASONOGRAPHY. Fetal Activity,Fetal Activities,Fetal Movements
D005865 Gestational Age The age of the conceptus, beginning from the time of FERTILIZATION. In clinical obstetrics, the gestational age is often estimated from the onset of the last MENSTRUATION which is about 2 weeks before OVULATION and fertilization. It is also estimated to begin from fertilization, estrus, coitus, or artificial insemination. Embryologic Age,Fetal Maturity, Chronologic,Chronologic Fetal Maturity,Fetal Age,Maturity, Chronologic Fetal,Age, Embryologic,Age, Fetal,Age, Gestational,Ages, Embryologic,Ages, Fetal,Ages, Gestational,Embryologic Ages,Fetal Ages,Gestational Ages
D006340 Heart Rate, Fetal The heart rate of the FETUS. The normal range at term is between 120 and 160 beats per minute. Fetal Heart Rate,Fetal Heart Rates,Heart Rates, Fetal,Rate, Fetal Heart,Rates, Fetal Heart
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

Lauren M Jansson, and Martha Velez, and Krystle McConnell, and Nancy Spencer, and Michelle Tuten, and Hendree E Jones, and Van L King, and Neeraj Gandotra, and Lorraine A Milio, and Kristin Voegtline, and Janet A DiPietro
September 2002, Developmental psychology,
Lauren M Jansson, and Martha Velez, and Krystle McConnell, and Nancy Spencer, and Michelle Tuten, and Hendree E Jones, and Van L King, and Neeraj Gandotra, and Lorraine A Milio, and Kristin Voegtline, and Janet A DiPietro
October 1996, Child development,
Lauren M Jansson, and Martha Velez, and Krystle McConnell, and Nancy Spencer, and Michelle Tuten, and Hendree E Jones, and Van L King, and Neeraj Gandotra, and Lorraine A Milio, and Kristin Voegtline, and Janet A DiPietro
September 2009, Clinical obstetrics and gynecology,
Lauren M Jansson, and Martha Velez, and Krystle McConnell, and Nancy Spencer, and Michelle Tuten, and Hendree E Jones, and Van L King, and Neeraj Gandotra, and Lorraine A Milio, and Kristin Voegtline, and Janet A DiPietro
August 2018, Development and psychopathology,
Lauren M Jansson, and Martha Velez, and Krystle McConnell, and Nancy Spencer, and Michelle Tuten, and Hendree E Jones, and Van L King, and Neeraj Gandotra, and Lorraine A Milio, and Kristin Voegtline, and Janet A DiPietro
January 1999, The Journal of perinatal education,
Lauren M Jansson, and Martha Velez, and Krystle McConnell, and Nancy Spencer, and Michelle Tuten, and Hendree E Jones, and Van L King, and Neeraj Gandotra, and Lorraine A Milio, and Kristin Voegtline, and Janet A DiPietro
March 2012, The Lancet. Oncology,
Lauren M Jansson, and Martha Velez, and Krystle McConnell, and Nancy Spencer, and Michelle Tuten, and Hendree E Jones, and Van L King, and Neeraj Gandotra, and Lorraine A Milio, and Kristin Voegtline, and Janet A DiPietro
July 1998, Developmental psychobiology,
Lauren M Jansson, and Martha Velez, and Krystle McConnell, and Nancy Spencer, and Michelle Tuten, and Hendree E Jones, and Van L King, and Neeraj Gandotra, and Lorraine A Milio, and Kristin Voegtline, and Janet A DiPietro
May 2022, Toxicology,
Lauren M Jansson, and Martha Velez, and Krystle McConnell, and Nancy Spencer, and Michelle Tuten, and Hendree E Jones, and Van L King, and Neeraj Gandotra, and Lorraine A Milio, and Kristin Voegtline, and Janet A DiPietro
March 2024, Pharmaceutics,
Lauren M Jansson, and Martha Velez, and Krystle McConnell, and Nancy Spencer, and Michelle Tuten, and Hendree E Jones, and Van L King, and Neeraj Gandotra, and Lorraine A Milio, and Kristin Voegtline, and Janet A DiPietro
September 2020, Journal of psychosomatic obstetrics and gynaecology,
Copied contents to your clipboard!